Therapeutic potential of the interleukin-4/interleukin-13 inhibitor dupilumab for treating IgG4-related disease.
作者信息
Nakajima Isana, Taniguchi Yoshinori, Tsuji Hideki, Mizobuchi Tomoka, Fukuda Ken
机构信息
Department of Ophthalmology and Visual Science.
Department of Endocrinology, Metabolism, and Nephrology, Kochi Medical School, Kochi University, Nankoku City, Kochi.
出版信息
Rheumatology (Oxford). 2022 May 30;61(6):e151-e153. doi: 10.1093/rheumatology/keab950.
PMID:34962989
Abstract
摘要
相似文献
1
Therapeutic potential of the interleukin-4/interleukin-13 inhibitor dupilumab for treating IgG4-related disease.白细胞介素-4/白细胞介素-13抑制剂度普利尤单抗治疗IgG4相关疾病的治疗潜力。
Rheumatology (Oxford). 2022 May 30;61(6):e151-e153. doi: 10.1093/rheumatology/keab950.
2
Dupilumab as a novel steroid-sparing treatment for IgG4-related disease.度普利尤单抗作为一种用于IgG4相关疾病的新型类固醇节省疗法。
Ann Rheum Dis. 2020 Apr;79(4):549-550. doi: 10.1136/annrheumdis-2019-216368. Epub 2019 Dec 19.
3
Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis.度普利尤单抗的疗效揭示了IgG4相关疾病的治疗靶点：同时控制炎症和纤维化。
Ann Rheum Dis. 2022 Mar;81(3):e50. doi: 10.1136/annrheumdis-2020-217076. Epub 2020 Feb 7.
4
A case of IgG4-related dacryoadenitis and sialoadenitis remitted by dupilumab monotherapy.1例经度普利尤单抗单药治疗缓解的IgG4相关性泪腺炎和涎腺炎病例。
Rheumatology (Oxford). 2024 May 3;63(6):e188-e189. doi: 10.1093/rheumatology/kead680.
5
Successful treatment of IgG4-related disease with tocilizumab monotherapy.托珠单抗单药治疗IgG4相关疾病取得成功。
Autoimmun Rev. 2023 Apr;22(4):103296. doi: 10.1016/j.autrev.2023.103296. Epub 2023 Feb 11.
6
Correspondence on: 'Dupilumab as a novel steroid-sparing treatment for IgG-related disease' by Simpson .关于辛普森所著《度普利尤单抗作为一种用于IgG相关疾病的新型类固醇节省疗法》的通信
Ann Rheum Dis. 2022 Feb;81(2):e26. doi: 10.1136/annrheumdis-2020-217010. Epub 2020 Jan 29.
7
Response to: 'Dupilumab as a steroid-sparing treatment for IgG4-related disease' by Della-Torre .对德拉 - 托雷的《度普利尤单抗作为IgG4相关疾病的类固醇节省治疗方法》的回应
Ann Rheum Dis. 2022 Feb;81(2):e25. doi: 10.1136/annrheumdis-2020-216955. Epub 2020 Feb 7.
8
B-cell depletion with obinutuzumab for the treatment of IgG4-related disease.使用奥妥珠单抗进行B细胞清除治疗IgG4相关疾病。
Eur J Intern Med. 2023 Oct;116:155-156. doi: 10.1016/j.ejim.2023.07.019. Epub 2023 Jul 21.
9
Two cases of refractory IgG4-related disease successfully treated with tocilizumab.两例难治性IgG4相关疾病经托珠单抗治疗成功
Ann Hematol. 2022 Jul;101(7):1593-1594. doi: 10.1007/s00277-022-04787-x. Epub 2022 Feb 13.
10
Dupilumab as a steroid-sparing treatment for IgG4-related disease.度普利尤单抗作为IgG4相关性疾病的一种激素替代治疗药物。
Ann Rheum Dis. 2022 Feb;81(2):e24. doi: 10.1136/annrheumdis-2020-216945. Epub 2020 Jan 14.
引用本文的文献
1
An Unusual Case of Chylous Ascites.一例罕见的乳糜性腹水病例。
Cureus. 2024 Dec 19;16(12):e76018. doi: 10.7759/cureus.76018. eCollection 2024 Dec.
2
Interleukin in Immune-Mediated Diseases: An Updated Review.免疫介导疾病中的白细胞介素：最新综述
Mol Biotechnol. 2024 Dec 23. doi: 10.1007/s12033-024-01347-8.
3
IgG4-related Disease: Recent Topics on Immunological Aspects of This Disorder and Their Application in New Treatment Strategies.IgG4相关性疾病：该疾病免疫方面的最新话题及其在新治疗策略中的应用
Intern Med. 2025 Jan 1;64(1):31-39. doi: 10.2169/internalmedicine.3154-23. Epub 2024 Feb 19.
4
A case of IgG4-related dacryoadenitis and sialoadenitis remitted by dupilumab monotherapy.1例经度普利尤单抗单药治疗缓解的IgG4相关性泪腺炎和涎腺炎病例。
Rheumatology (Oxford). 2024 May 3;63(6):e188-e189. doi: 10.1093/rheumatology/kead680.
5
Long-term efficacy of anti-IL-4 receptor antibody in a patient with aspirin-exacerbated respiratory disease and IgG4-related disease.抗白细胞介素-4受体抗体治疗阿司匹林加重性呼吸系统疾病合并IgG4相关性疾病患者的长期疗效
Allergy Asthma Clin Immunol. 2023 Aug 5;19(1):67. doi: 10.1186/s13223-023-00825-z.
6
IgG4-related disease administered dupilumab: case series and review of the literature.IgG4 相关疾病应用度普利尤单抗：病例系列和文献复习。
RMD Open. 2023 Mar;9(1). doi: 10.1136/rmdopen-2023-003026.
Zotero 插件